
“The quality and coverage of B2B contact database are very impressive...”
Mark J.
`
+4
Mesoblast (ASX:MSB; Nasdaq:MESO) is developing and commercializing allogeneic cellular medicines to treat serious and life-threatening inflammatory diseases with significant, unmet medical needs. The Companys Phase 3 off-the-shelf mesenchymal lineage cell product candidates are: RYONCILTM (remestemcel-L) for steroid-refractory acute graft versus host disease (acute GVHD) Remestemcel-L for moderate to severe acute respiratory distress syndrome (ARDS) due to COVID-19 infection REVASCOR for advanced chronic heart failure, and MPC-06-ID for chronic low back pain due to degenerative disc disease. The Companys proprietary manufacturing processes yield industrial-scale, cryopreserved, off-the-shelf, cellular medicines. These cell therapies, with defined pharmaceutical release criteria, are planned to be readily...
Cell-based therapies,cellular medicines,mesenchymal lineage adult stem cells,regenerative medicine,covid-19,chronic heart failure,graft versus host disease,chronic low back pain,and rheumatoid arthritis
Mesoblast limited operates in the Biotechnology research industry.
Mesoblast limited's revenue is 1m - 10m
Mesoblast limited has 51 - 200 employees.
Get Started with the Free Forever plan! No credit card needed. Enjoy up to 10,000 free email credits per month at no cost.
Start Prospecting from Clodura.AI's database of 600M+ verified B2B contacts and 120M+ direct dials along with 18M+ companies' org charts.
Unlock the prospect's contact details, including verified email, direct dials, add them to cadence, and close more deals.